Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases, today announced
financial results for the third quarter of 2023, and associated
Company developments.
“Our third-quarter performance underscores the
strength of our growth products, with combined Qelbree and GOCOVRI
net product sales increasing 52% in the third quarter of 2023
compared to the same period last year,” said Jack Khattar,
President and CEO of Supernus. “In addition to our strong
commercial execution, during our R&D Day in October 2023, we
highlighted our pipeline of first-in-class differentiated CNS
product candidates that have the potential to bolster future
growth.”
Qelbree Update
- Total
IQVIA prescriptions were 163,344 in the third quarter of 2023, an
increase of 73% compared to the same period last year and 12%
compared to the second quarter of 2023.
- Qelbree
continues to expand its base of prescribers, with approximately
24,189 prescribers in the third quarter of 2023, up from 21,291
prescribers in the second quarter of 2023.
- The
Company presented new data at Psych Congress 2023 in September
showing improved efficacy in children ages 6 years and older with
attention-deficit hyperactivity disorder (ADHD) when Qelbree is
administered with stimulants, as well as in adults with ADHD who
undergo long-term treatment with Qelbree.
___________________________________________(1) Adjusted
Operating Earnings is a non-GAAP measure and is calculated as
Operating Earnings (Loss) (GAAP) plus amortization of intangible
assets, share-based compensation, contingent consideration expense
(gain) and depreciation. A reconciliation of the full year 2023
financial guidance for Operating Loss (GAAP) to Adjusted Operating
Earnings (non-GAAP) is included under the heading “Full Year 2023
Financial Guidance – GAAP to Non-GAAP Adjustments.”(2)
Total revenues, excluding Trokendi XR net product sales is a
non-GAAP measure and is calculated as total revenues (GAAP) less
net product sales of Trokendi XR (GAAP). A reconciliation of this
measure to Total revenues (GAAP) is included under the heading
“Reconciliation of GAAP Total revenues to Non-GAAP Total revenues
excluding Trokendi XR net product sales.”
Product Pipeline Update
The Company hosted a successful Research &
Development (R&D) Day in October 2023 highlighting clinical and
R&D progress and its emerging pipeline of novel CNS product
candidates. During the R&D Day the Company provided a product
pipeline update as set forth below:
SPN-830 (apomorphine infusion device) for treatment of PD
- In
November 2023, the FDA accepted the resubmission of the New Drug
Application (NDA) for SPN-830 for continuous treatment of motor
fluctuations ("off" episodes) in Parkinson's disease (PD). The
resubmission is now considered filed, with a user fee goal date
(PDUFA date) of April 5, 2024.
SPN-820 – Novel first-in-class molecule that
increases mTORC1 mediated synaptic function for depression
- The
Phase IIb multi-center randomized double-blind placebo-controlled
parallel design study of SPN-820 in adults with treatment-resistant
depression is ongoing. The study will examine the efficacy and
safety of SPN-820 over a course of five weeks of treatment in
approximately 268 patients in up to 50 clinical sites. The primary
outcome measure is the change from baseline to end of treatment
period on the Montgomery-Asberg Depression Rating Scale (MADRS)
Total Score. Topline data from the Phase IIb trial is expected in
2025.
- The Company plans to initiate a
Phase II open-label study in approximately 40 subjects with major
depressive disorder (MDD) before year-end 2023. The primary
objective of the study is to assess efficacy in MDD, as well as
onset of efficacy.
SPN-817 – Novel first-in-class highly selective AChE inhibitor
for epilepsy
- An
open-label Phase IIa clinical study of SPN-817 for
treatment-resistant seizures is ongoing. The study is examining the
safety and tolerability of SPN-817 as adjunctive therapy in adult
patients with treatment-resistant seizures, as well as assessing
efficacy. The Company expects topline results from the Phase IIa
study in the first half of 2024.
- The
Company expects to initiate a Phase IIb randomized, double-blind,
placebo-controlled study in approximately 436 patients with
treatment-resistant focal seizures in the first half of 2024. The
primary endpoint is change from baseline in focal seizure frequency
per 28 days. Topline results from the Phase IIb study are expected
in 2026.
SPN-443 – Novel stimulant for ADHD/CNS
- The
Company is planning in 2024 to initiate a Phase I single dose study
in approximately 24 healthy adults following submission of an
Investigational New Drug (IND) application. The primary objective
of the study is to assess safety and tolerability.
Financial Highlights
Total revenues (GAAP and non-GAAP)
For the three months ended September 30, 2023,
total revenues and total net product sales (GAAP) were $153.9
million and $149.0 million, respectively, compared to total
revenues and total net product sales of $177.4 million and $172.7
million for the same period in 2022. For the nine months ended
September 30, 2023, total revenues and total net product sales were
$443.2 million and $417.9 million, respectively, compared to total
revenues and total net product sales of $499.9 million and $485.6
million for the same period in 2022. The decrease in net product
sales in both periods was primarily due to the decline in net
product sales of Trokendi XR. This decline in net product sales of
Trokendi XR was partially offset by an increase in net product
sales of Qelbree, GOCOVRI and APOKYN for the three months ended
September 30, 2023, and an increase in net product sales of Qelbree
and GOCOVRI for the nine months ended September 30, 2023.
Total revenues excluding Trokendi XR net product
sales (non-GAAP) for the three and nine months ended September 30,
2023, increased 24% and 25%, respectively, compared to the same
periods in 2022.
The following table provides information
regarding total revenues during the three and nine months ended
September 30, 2023 and 2022 (unaudited, dollars in millions):
|
Three Months EndedSeptember
30, |
|
|
Nine Months EndedSeptember
30, |
|
|
|
|
2023 |
|
|
2022 |
|
Change % |
|
|
2023 |
|
|
2022 |
|
Change % |
Total net product sales |
$ |
149.0 |
|
$ |
172.7 |
|
(14 |
)% |
|
$ |
417.9 |
|
$ |
485.6 |
|
(14 |
)% |
Royalty revenues(1) |
|
4.9 |
|
|
4.7 |
|
4 |
% |
|
|
25.3 |
|
|
14.3 |
|
77 |
% |
Total revenues (GAAP) |
$ |
153.9 |
|
$ |
177.4 |
|
(13 |
)% |
|
$ |
443.2 |
|
$ |
499.9 |
|
(11 |
)% |
Total revenues excluding Trokendi
XR net product sales (non-GAAP) |
$ |
133.3 |
|
$ |
107.8 |
|
24 |
% |
|
$ |
368.5 |
|
$ |
295.9 |
|
25 |
% |
___________________________________________(1)
Royalty revenues include royalties on generic Trokendi XR, other
licensed products and intellectual property.
The following table provides information
regarding total net product sales during the three and nine months
ended September 30, 2023 and 2022 (unaudited, dollars in
millions):
|
Three Months EndedSeptember
30, |
|
|
Nine Months EndedSeptember
30, |
|
|
|
|
2023 |
|
|
2022 |
|
Change % |
|
|
2023 |
|
|
2022 |
|
Change % |
Net product sales |
|
|
|
|
|
|
|
|
|
|
|
Qelbree |
$ |
37.1 |
|
$ |
18.3 |
|
103 |
% |
|
$ |
93.8 |
|
$ |
37.7 |
|
149 |
% |
GOCOVRI |
|
32.9 |
|
|
27.9 |
|
18 |
% |
|
|
87.7 |
|
|
75.2 |
|
17 |
% |
Oxtellar XR® |
|
29.6 |
|
|
30.5 |
|
(3 |
)% |
|
|
82.4 |
|
|
88.0 |
|
(6 |
)% |
Trokendi XR |
|
20.6 |
|
|
69.6 |
|
(70 |
)% |
|
|
74.7 |
|
|
204.0 |
|
(63 |
)% |
APOKYN® |
|
21.5 |
|
|
18.3 |
|
17 |
% |
|
|
56.3 |
|
|
57.2 |
|
(2 |
)% |
Other(1) |
|
7.3 |
|
|
8.1 |
|
(10 |
)% |
|
|
23.0 |
|
|
23.5 |
|
(2 |
)% |
Total net product sales |
$ |
149.0 |
|
$ |
172.7 |
|
(14 |
)% |
|
$ |
417.9 |
|
$ |
485.6 |
|
(14 |
)% |
___________________________________________(1)
Includes net product sales of MYOBLOC®, XADAGO® and Osmolex
ER®.
Operating earnings (loss) (GAAP and
non-GAAP)
For the three months ended September 30, 2023,
operating earnings (GAAP) was $8.1 million, compared to operating
loss (GAAP) of ($1.5) million for the same period in 2022. For the
nine months ended September 30, 2023, operating loss (GAAP) was
($4.3) million, compared to operating earnings (GAAP) of $11.8
million for the same period in 2022. The increase in operating
earnings (GAAP) in the third quarter of 2023 was due primarily to
lower selling and marketing expenses compared to the third quarter
of 2022 due to the launch of Qelbree to the adult population and
the Qelbree direct-to-consumer campaign, which substantially
occurred in the third quarter of 2022. The operating loss (GAAP) in
the nine months ended September 30, 2023 was primarily due to a
decrease in net product sales of Trokendi XR, partially offset by
growth in net product sales of Qelbree and GOCOVRI, and a decrease
in operating expenses.
For the three months ended September 30, 2023,
adjusted operating earnings (non-GAAP) were $37.3 million, compared
to $25.4 million for the same period in 2022. For the nine months
ended September 30, 2023, adjusted operating earnings (non-GAAP)
were $77.9 million, compared to $91.1 million for the same period
in 2022.
Reconciliation of GAAP Operating earnings (loss)
to Non-GAAP Operating earnings
An itemized reconciliation between operating
earnings (loss) on a GAAP basis and operating earnings on a
non-GAAP basis is as follows (unaudited, dollars in millions):
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
Operating earnings
(loss) - As Reported (GAAP) |
$ |
8.1 |
|
|
$ |
(1.5 |
) |
|
$ |
(4.3 |
) |
|
$ |
11.8 |
Adjustments: |
|
|
|
|
|
|
|
Amortization of intangible assets |
|
21.2 |
|
|
|
20.6 |
|
|
|
61.3 |
|
|
|
61.9 |
Share-based compensation |
|
7.9 |
|
|
|
5.0 |
|
|
|
20.3 |
|
|
|
13.3 |
Contingent consideration expense (gain) |
|
(0.5 |
) |
|
|
0.5 |
|
|
|
(1.3 |
) |
|
|
1.9 |
Depreciation |
|
0.6 |
|
|
|
0.8 |
|
|
|
1.9 |
|
|
|
2.2 |
Operating earnings -
As Adjusted (non-GAAP) |
$ |
37.3 |
|
|
$ |
25.4 |
|
|
$ |
77.9 |
|
|
$ |
91.1 |
Non-GAAP operating earnings adjusts for non-cash
items including amortization of intangible assets, share-based
compensation expense, change in fair value of contingent
consideration, and depreciation.
Net earnings (loss) (GAAP)
For the three months ended September 30, 2023,
net earnings (loss) (GAAP) and diluted earnings (loss) per share
(GAAP) were ($16.0) million and ($0.29), respectively, as compared
to $1.7 million and $0.03, in the same period in 2022. For the nine
months ended September 30, 2023, net earnings (GAAP) and diluted
earnings per share (GAAP) were $0.1 million and $0.00,
respectively, as compared to $35.2 million and $0.62 in the same
period in 2022.
Balance sheet
At September 30, 2023, the Company's cash, cash
equivalents, and current and long-term marketable securities were
approximately $225.3 million, compared to $555.2 million as of
December 31, 2022. This decrease was primarily due to repayment of
the Company's $402.5 million 0.625% Convertible Senior Notes
due 2023 (2023 Notes), partially offset by cash generated from
operations.
Full Year 2023 Financial Guidance (GAAP)
The Company is revising its full-year 2023
financial guidance as set forth below (dollars in millions).
|
Current(as of November 8,
2023) |
|
Previous(as of August 8,
2023) |
Total revenues(1)(2) |
$590 - $610 |
|
$580 - $620 |
Combined R&D and SG&A
expenses |
$420 - $440 |
|
$450 - $480 |
Operating loss(3) |
($15) - ($5) |
|
($30) - ($10) |
___________________________________________(1) Includes net
product sales and royalty revenue, and approximately $90 million of
Trokendi XR.(2) Reflects Trokendi XR generic erosion in 2023.(3)
Includes amortization of intangible assets and contingent
consideration expense (gain).
Full Year 2023 Financial Guidance - GAAP to Non-GAAP
Adjustments
An itemized reconciliation between projected
operating loss on a GAAP basis and projected operating earnings on
a non-GAAP basis is as follows (dollars in millions):
|
Current(as of November 8,
2023) |
|
Previous(as of August 8,
2023) |
Operating loss -
GAAP |
($15) - ($5) |
|
($30) - ($10) |
Adjustments: |
|
|
|
Amortization of intangible assets |
$83 |
|
$83 |
Share-based compensation |
$25 - $29 |
|
$20 - $24 |
Contingent consideration |
$0 - $1 |
|
$0 - $1 |
Depreciation |
$2 |
|
$2 |
Operating earnings -
non-GAAP |
$95 - $110 |
|
$75 - $100 |
Non-GAAP Financial Information
This press release contains financial measures
that present financial information which do not comply with United
States generally accepted accounting principles (GAAP). The
non-GAAP financial measure should be considered in addition to, not
as a substitute for or in isolation from, or superior to measures
prepared in accordance with GAAP. Non-GAAP operating earnings
adjusts for non-cash share-based compensation expense, depreciation
and amortization, and accretion of contingent consideration, and
for factors that are unusual, non-recurring or unpredictable, and
excludes those costs, expenses, and other specified items presented
in the reconciliation tables in this press release. In addition to
non-GAAP operating earnings, we also present total revenues
excluding net product sales of Trokendi XR which is a non-GAAP
measure and is calculated as total revenues (GAAP) less net product
sales of Trokendi XR (GAAP). With the loss of exclusivity due to
generic entrants, we do not expect net product sales of Trokendi XR
to constitute a significant part of our revenue in the future. We
believe that the use of non-GAAP financial measures provides useful
supplemental information to management, investors, analysts and
others regarding the Company’s revenue and results of operations
and assist management, investors, analysts, and others in
understanding and evaluating our revenue growth and the performance
of the business.
There are limitations associated with the use of
non-GAAP financial measures and therefore comparability may be
limited. These limitations include: non-GAAP financial measures
that may not be entirely comparable to similarly titled measures
used by other companies; these may not reflect all items of income
and expense, as applicable, that affect our operations; there may
be potential differences among calculation methodologies; these may
differ from the non-GAAP information used by other companies,
including peer companies. We mitigate these limitations by
reconciling the non-GAAP financial measure to the most comparable
GAAP financial measure. Investors are encouraged to review the
reconciliation. The Company’s 2023 financial guidance is also being
provided on both a reported and a non-GAAP basis.
Reconciliation of GAAP Total revenues to
Non-GAAP Total revenues excluding Trokendi XR net product sales
An itemized reconciliation between total
revenues on a GAAP basis and Total revenues excluding Trokendi XR
net product sales, a non-GAAP measure, is as follows (unaudited,
dollars in millions):
|
Three Months EndedSeptember
30, |
|
|
|
Nine Months EndedSeptember
30, |
|
|
|
|
2023 |
|
|
2022 |
|
Change % |
|
|
2023 |
|
|
2022 |
|
Change % |
Total revenues (GAAP)(1) |
$153.9 |
|
$177.4 |
|
(13 |
)% |
|
$443.2 |
|
$499.9 |
|
(11 |
)% |
Less: Trokendi XR net product sales |
|
20.6 |
|
|
69.6 |
|
(70 |
)% |
|
|
74.7 |
|
|
204.0 |
|
(63 |
)% |
Total revenues excluding
Trokendi XR net product sales (Non-GAAP) |
$133.3 |
|
$107.8 |
|
24 |
% |
|
$368.5 |
|
$295.9 |
|
25 |
% |
___________________________________________(1)
Includes net product sales and royalty revenue.
Conference Call Details
Supernus will host a conference call and webcast
today, November 8, 2023, at 4:30 p.m. Eastern Time to discuss these
results. A live webcast will be available in the Events &
Presentations section of the Company’s Investor Relations website
www.supernus.com/investors.
Participants may also pre-register any time
before the call here. Once registration is completed, participants
will be provided a dial-in number with a personalized conference
code to access the call. Please dial 15 minutes prior to the start
time.
Following the live call, a replay will be
available on the Company's Investor Relations website
www.supernus.com/investors. The webcast will be available on the
Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals,
Inc.
Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes
approved treatments for epilepsy, migraine, ADHD, hypomobility in
PD, cervical dystonia, chronic sialorrhea, dyskinesia in PD
patients receiving levodopa-based therapy, and drug-induced
extrapyramidal reactions in adult patients. We are developing a
broad range of novel CNS product candidates including new potential
treatments for hypomobility in PD, epilepsy, depression, and other
CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements do not convey historical
information but relate to predicted or potential future events that
are based upon management's current expectations. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
such statements. In addition to the factors mentioned in this press
release, such risks and uncertainties include, but are not limited
to, the Company’s ability to sustain and increase its
profitability; the Company’s ability to raise sufficient capital to
fully implement its corporate strategy; the implementation of the
Company’s corporate strategy; the Company’s future financial
performance and projected expenditures; the Company’s ability to
increase the number of prescriptions written for each of its
products and the products of its subsidiaries; the Company’s
ability to increase its net revenue; the Company’s ability to
commercialize its products and the products of its subsidiaries;
the Company’s ability to enter into future collaborations with
pharmaceutical companies and academic institutions or to obtain
funding from government agencies; the Company’s product research
and development activities, including the timing and progress of
the Company’s clinical trials, and projected expenditures; the
Company’s ability to receive, and the timing of any receipt of,
regulatory approvals to develop and commercialize the Company’s
product candidates; the Company’s ability to protect its
intellectual property and the intellectual property of its
subsidiaries and operate its business without infringing upon the
intellectual property rights of others; the Company’s expectations
regarding federal, state and foreign regulatory requirements; the
therapeutic benefits, effectiveness and safety of the Company’s
product candidates; the accuracy of the Company’s estimates of the
size and characteristics of the markets that may be addressed by
its product candidates; the Company’s ability to increase its
manufacturing capabilities for its products and product candidates;
the Company’s projected markets and growth in markets; the
Company’s product formulations and patient needs and potential
funding sources; the Company’s staffing needs; the Company’s
ability to increase the number of prescriptions written for each of
its products and the products of its subsidiaries; the Company’s
ability to increase its net revenue from its products and the
products of its subsidiaries; and other risk factors set forth from
time to time in the Company’s filings with the Securities and
Exchange Commission made pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended. The Company undertakes
no obligation to update the information in this press release to
reflect events or circumstances after the date hereof or to reflect
the occurrence of anticipated or unanticipated events.
Supernus Pharmaceuticals, Inc.Consolidated
Balance Sheets(in thousands, except share
data) |
|
|
September 30, |
|
December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
(unaudited) |
|
|
Assets |
|
|
|
Current assets |
|
|
|
Cash and cash equivalents |
$ |
94,985 |
|
|
$ |
93,120 |
|
Marketable securities |
|
105,204 |
|
|
|
368,214 |
|
Accounts receivable, net |
|
141,764 |
|
|
|
165,497 |
|
Inventories, net |
|
83,480 |
|
|
|
91,541 |
|
Prepaid expenses and other current assets |
|
23,927 |
|
|
|
15,779 |
|
Total current
assets |
|
449,360 |
|
|
|
734,151 |
|
Long-term marketable securities |
|
25,125 |
|
|
|
93,896 |
|
Property and equipment, net |
|
13,688 |
|
|
|
15,173 |
|
Intangible assets, net |
|
641,147 |
|
|
|
702,463 |
|
Goodwill |
|
117,019 |
|
|
|
117,019 |
|
Other assets |
|
38,821 |
|
|
|
39,806 |
|
Total
assets |
$ |
1,285,160 |
|
|
$ |
1,702,508 |
|
|
|
|
|
Liabilities and
stockholders’ equity |
|
|
|
Current liabilities |
|
|
|
Accounts payable and accrued liabilities |
$ |
78,471 |
|
|
$ |
96,342 |
|
Accrued product returns and rebates |
|
162,473 |
|
|
|
151,665 |
|
Convertible notes, net |
|
— |
|
|
|
401,968 |
|
Contingent consideration, current portion |
|
45,880 |
|
|
|
21,120 |
|
Other current liabilities |
|
710 |
|
|
|
16,863 |
|
Total current
liabilities |
|
287,534 |
|
|
|
687,958 |
|
Contingent consideration, long-term |
|
7,774 |
|
|
|
33,847 |
|
Operating lease liabilities, long-term |
|
33,841 |
|
|
|
35,998 |
|
Deferred income tax liabilities, net |
|
35,224 |
|
|
|
49,809 |
|
Other liabilities |
|
8,596 |
|
|
|
8,692 |
|
Total
liabilities |
|
372,969 |
|
|
|
816,304 |
|
|
|
|
|
Stockholders’
equity |
|
|
|
Common stock, $0.001 par value; 130,000,000 shares authorized;
54,630,758 and 54,253,796 shares issued and outstanding as of
September 30, 2023 and December 31, 2022, respectively |
|
55 |
|
|
|
54 |
|
Additional paid-in capital |
|
431,956 |
|
|
|
408,115 |
|
Accumulated other comprehensive loss, net of tax |
|
(1,206 |
) |
|
|
(3,210 |
) |
Retained earnings |
|
481,386 |
|
|
|
481,245 |
|
Total stockholders’
equity |
|
912,191 |
|
|
|
886,204 |
|
|
|
|
|
Total liabilities and
stockholders’ equity |
$ |
1,285,160 |
|
|
$ |
1,702,508 |
|
Supernus
Pharmaceuticals, Inc.Consolidated Statements
of Earnings (Loss)(in thousands, except share and
per share data) |
|
|
|
|
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
(unaudited) |
|
(unaudited) |
Revenues |
|
|
|
|
|
|
|
Net product sales |
$ |
149,004 |
|
|
$ |
172,724 |
|
|
$ |
417,915 |
|
|
$ |
485,647 |
|
Royalty revenues |
|
4,876 |
|
|
|
4,629 |
|
|
|
25,292 |
|
|
|
14,263 |
|
Total revenues |
|
153,880 |
|
|
|
177,353 |
|
|
|
443,207 |
|
|
|
499,910 |
|
|
|
|
|
|
|
|
|
Costs and expenses |
|
|
|
|
|
|
|
Cost of goods sold |
|
19,601 |
|
|
|
25,878 |
|
|
|
64,152 |
|
|
|
64,267 |
|
Research and development |
|
22,655 |
|
|
|
19,554 |
|
|
|
68,246 |
|
|
|
56,778 |
|
Selling, general and administrative |
|
82,700 |
|
|
|
112,314 |
|
|
|
255,079 |
|
|
|
303,249 |
|
Amortization of intangible assets |
|
21,242 |
|
|
|
20,644 |
|
|
|
61,316 |
|
|
|
61,932 |
|
Contingent consideration expense (gain) |
|
(456 |
) |
|
|
486 |
|
|
|
(1,313 |
) |
|
|
1,894 |
|
Total costs and expenses |
|
145,742 |
|
|
|
178,876 |
|
|
|
447,480 |
|
|
|
488,120 |
|
|
|
|
|
|
|
|
|
Operating earnings (loss) |
|
8,138 |
|
|
|
(1,523 |
) |
|
|
(4,273 |
) |
|
|
11,790 |
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
Interest expense |
|
— |
|
|
|
(1,724 |
) |
|
|
(2,415 |
) |
|
|
(5,476 |
) |
Interest and other income, net |
|
1,751 |
|
|
|
2,803 |
|
|
|
8,467 |
|
|
|
19,289 |
|
Total other income (expense) |
|
1,751 |
|
|
|
1,079 |
|
|
|
6,052 |
|
|
|
13,813 |
|
|
|
|
|
|
|
|
|
Earnings (loss) before income
taxes |
|
9,889 |
|
|
|
(444 |
) |
|
|
1,779 |
|
|
|
25,603 |
|
|
|
|
|
|
|
|
|
Income tax expense (benefit) |
|
25,865 |
|
|
|
(2,193 |
) |
|
|
1,638 |
|
|
|
(9,627 |
) |
Net earnings (loss) |
$ |
(15,976 |
) |
|
$ |
1,749 |
|
|
$ |
141 |
|
|
$ |
35,230 |
|
|
|
|
|
|
|
|
|
Earnings (loss) per share |
|
|
|
|
|
|
|
Basic |
$ |
(0.29 |
) |
|
$ |
0.03 |
|
|
$ |
0.00 |
|
|
$ |
0.66 |
|
Diluted |
$ |
(0.29 |
) |
|
$ |
0.03 |
|
|
$ |
0.00 |
|
|
$ |
0.62 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding |
|
|
|
|
|
|
|
Basic |
|
54,608,963 |
|
|
|
53,789,674 |
|
|
|
54,498,687 |
|
|
|
53,517,838 |
|
Diluted |
|
54,608,963 |
|
|
|
55,034,838 |
|
|
|
55,574,922 |
|
|
|
61,543,121 |
|
CONTACTS:
Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice
President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591
or
INVESTOR CONTACT:Peter VozzoICR WestwickeOffice: (443)
213-0505Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024